Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich to Acquire Nucleic Acid Manufacturer Proligo

NEW YORK, Feb. 16 (GenomeWeb News) - Sigma-Aldrich plans to purchase DNA and RNA maker Proligo from Degussa, the company said today.

 

Financial and other terms of the proposed acquisition were not disclosed.

 

Proligo, headquartered in Boulder, Colo., provides custom DNA, RNA, and raw materials for DNA and RNA synthesis. The company is one of four exclusive licensees to an RNAi patent application owned by MIT.

 

Last year, Proligo had approximately $40 million in sales. The company has manufacturing sites in Boulder, France, Germany, Singapore, Japan, and Australia, and has about 300 employees.

 

"We expect this investment to permit us to participate as a global leader in the genomics and gene-silencing research tools markets for years to come," said David Harvey, Sigma's CEO, in a statement.

 

The acquisition, which Sigma plans to fund with short-term debt, has already been cleared with both companies' boards of directors. Subject to regulatory approval in Germanyand other terms and conditions, the deal is expected to close early in the second quarter of this year.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.